Two longitudinal studies suggest that cognitively intact APOE4 carriers are not at heightened risk for developing depression over 7.7 or 12 years among those who were aged 21–86 (mostly 50–69) or 20–64 years at baseline [44, 45]. This evidence concerns the gene APOE and depressive symptom measurement.